HMGB1 and Dystrophic epidermolysis bullosa: Moreover, HMGB1 peptide is being evaluated in clinical trials in Japan (S-005151, Redasemtide) for dystrophic epidermolysis bullosa (phase II) and acute ischemic stroke (phase II).